$ADMA
ADMA BIOLOGICS, INC.

2024 Q2 Form 10-Q Financial Statement

#000114036124025226 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $107.2M $81.88M $56.91M
YoY Change 78.29% 43.86% 95.56%
Cost Of Revenue $49.74M $42.77M $40.40M
YoY Change 14.52% 5.86% 58.8%
Gross Profit $57.45M $39.11M $16.51M
YoY Change 244.24% 136.83% 350.92%
Gross Profit Margin 53.6% 47.77% 29.01%
Selling, General & Admin $16.61M $15.64M $14.51M
YoY Change 16.57% 7.77% 5.93%
% of Gross Profit 28.91% 39.99% 87.88%
Research & Development $560.0K $450.0K $855.4K
YoY Change -60.09% -47.39% 37.05%
% of Gross Profit 0.97% 1.15% 5.18%
Depreciation & Amortization $1.900M $1.900M $1.900M
YoY Change 0.0% 0.0% 35.71%
% of Gross Profit 3.31% 4.86% 11.51%
Operating Expenses $18.25M $17.29M $17.33M
YoY Change 6.34% -0.23% -6.23%
Operating Profit $39.20M $21.82M -$813.3K
YoY Change -8386.39% -2782.96% -94.51%
Interest Expense -$3.334M $3.769M $6.115M
YoY Change -152.93% -38.37% 80.45%
% of Operating Profit -8.5% 17.27%
Other Income/Expense, Net -$3.350M -$3.420M -$5.975M
YoY Change -43.2% -42.77% -41.38%
Pretax Income $35.85M $18.40M -$6.789M
YoY Change -662.75% -371.05% -72.85%
Income Tax $3.800M $600.0K $0.00
% Of Pretax Income 10.6% 3.26%
Net Earnings $32.06M $17.81M -$6.789M
YoY Change -603.27% -362.28% -72.85%
Net Earnings / Revenue 29.91% 21.75% -11.93%
Basic Earnings Per Share $0.14 $0.08 -$0.03
Diluted Earnings Per Share $0.13 $0.08 -$0.03
COMMON SHARES
Basic Shares Outstanding 231.8M 228.2M 222.2M
Diluted Shares Outstanding 242.2M 236.4M 221.9M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $88.24M $45.33M $69.20M
YoY Change 41.16% -34.51% -0.43%
Cash & Equivalents $88.20M $45.33M $69.20M
Short-Term Investments
Other Short-Term Assets $5.524M $3.741M $4.379M
YoY Change 5.85% -14.56% -20.67%
Inventory $179.8M $177.7M $164.0M
Prepaid Expenses
Receivables $30.10M $49.60M $26.52M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $303.7M $276.4M $264.1M
YoY Change 14.07% 4.67% 10.13%
LONG-TERM ASSETS
Property, Plant & Equipment $54.33M $55.32M $57.37M
YoY Change -3.52% -3.58% 7.8%
Goodwill $3.500M $3.500M $3.530M
YoY Change 0.0% -0.84%
Intangibles $479.0K $321.0K $834.6K
YoY Change -26.95% -61.54%
Long-Term Investments
YoY Change
Other Assets $5.221M $5.891M $4.719M
YoY Change -16.98% 24.84% 66.99%
Total Long-Term Assets $72.71M $74.46M $76.70M
YoY Change -5.31% -2.93% 12.41%
TOTAL ASSETS
Total Short-Term Assets $303.7M $276.4M $264.1M
Total Long-Term Assets $72.71M $74.46M $76.70M
Total Assets $376.4M $350.9M $340.8M
YoY Change 9.73% 2.96% 10.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.18M $17.19M $12.96M
YoY Change 17.33% 32.64% -8.21%
Accrued Expenses $26.58M $32.40M $21.59M
YoY Change -3.46% 50.11% 51.81%
Deferred Revenue $1.130M $1.118M $142.8K
YoY Change 691.13% 682.73%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.20M $53.10M $36.73M
YoY Change 5.36% 44.58% 16.35%
LONG-TERM LIABILITIES
Long-Term Debt $131.1M $130.8M $144.3M
YoY Change -6.58% -9.32% 4.25%
Other Long-Term Liabilities $390.0K $405.0K $338.7K
YoY Change -13.24% 19.56% -96.95%
Total Long-Term Liabilities $390.0K $405.0K $338.7K
YoY Change -13.24% 19.56% -99.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.20M $53.10M $36.73M
Total Long-Term Liabilities $390.0K $405.0K $338.7K
Total Liabilities $188.1M $197.2M $195.1M
YoY Change -4.14% 1.04% 7.75%
SHAREHOLDERS EQUITY
Retained Earnings -$456.4M -$488.5M -$484.8M
YoY Change -7.08% 0.75%
Common Stock $23.00K $23.00K $22.23K
YoY Change 2.44% 3.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $188.3M $153.7M $145.7M
YoY Change
Total Liabilities & Shareholders Equity $376.4M $350.9M $340.8M
YoY Change 9.73% 2.96% 10.63%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income $32.06M $17.81M -$6.789M
YoY Change -603.27% -362.28% -72.85%
Depreciation, Depletion And Amortization $1.900M $1.900M $1.900M
YoY Change 0.0% 0.0% 35.71%
Cash From Operating Activities $45.65M -$2.218M -$14.72M
YoY Change -853.39% -84.93% -43.41%
INVESTING ACTIVITIES
Capital Expenditures $2.365M $2.347M $1.945M
YoY Change 171.02% 20.69% -31.58%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.365M -$2.362M -$1.945M
YoY Change 171.02% 21.46% -31.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -362.0K -1.447M -650.5K
YoY Change -250.76% 122.44% -101.38%
NET CHANGE
Cash From Operating Activities 45.65M -2.218M -14.72M
Cash From Investing Activities -2.365M -2.362M -1.945M
Cash From Financing Activities -362.0K -1.447M -650.5K
Net Change In Cash 42.92M -6.027M -17.32M
YoY Change -741.42% -65.2% -194.04%
FREE CASH FLOW
Cash From Operating Activities $45.65M -$2.218M -$14.72M
Capital Expenditures $2.365M $2.347M $1.945M
Free Cash Flow $43.28M -$4.565M -$16.67M
YoY Change -724.42% -72.61% -42.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
42767000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
40401000
CY2024Q1 us-gaap Gross Profit
GrossProfit
39108000
CY2023Q1 us-gaap Gross Profit
GrossProfit
16513000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
450000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
855000
CY2024Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1005000
CY2023Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1780000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
17326000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
21821000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-813000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
384000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
166000
CY2024Q1 us-gaap Interest Expense
InterestExpense
3769000
CY2023Q1 us-gaap Interest Expense
InterestExpense
6115000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-35000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-27000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3420000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5976000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
17806000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6789000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
81875000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56914000
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
193000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
179000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15639000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14512000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
17287000
CY2024Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5232000
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4911000
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
321000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5217000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4718000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
499000
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
162000
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
56000
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001368514
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
18401000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6789000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
595000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
228874847
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
221921750
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
236414374
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
221921750
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
135206000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2141000
CY2024Q1 adma Stock Issued During Period Value Cashless Exercise Of Warrants
StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
0
CY2024Q1 adma Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes Amount
VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
-2476000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1029000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
17806000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
153706000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
151974000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1110000
CY2023Q1 adma Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes Amount
VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
-640000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6789000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
145655000
CY2024Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
45300000
CY2024Q1 adma Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts
AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
200000
CY2023Q4 adma Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts
AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
100000
CY2023Q4 us-gaap Goodwill
Goodwill
3500000
CY2024Q1 us-gaap Goodwill
Goodwill
3500000
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
17806000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
228874847
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
228874847
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
236414374
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2024Q1 adma Dilutive Securities Excluded From Computation Of Earnings Per Share Amount Shares
DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares
0
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28346315
CY2024Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q1 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2023Q1 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
56000
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
47000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
83964000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
80572000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
28647000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
26737000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
55317000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53835000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1900000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1900000
CY2024Q1 adma Accrued Rebates Current
AccruedRebatesCurrent
17330000
CY2023Q4 adma Accrued Rebates Current
AccruedRebatesCurrent
16608000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7100000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5954000
CY2024Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1220000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4961000
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
3478000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
546000
CY2024Q1 adma Accrued Testing Current
AccruedTestingCurrent
329000
CY2023Q4 adma Accrued Testing Current
AccruedTestingCurrent
282000
CY2024Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1853000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2203000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2381000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2365000
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
33691000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
32919000
CY2024Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
4153000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
4406000
CY2024Q1 us-gaap Senior Long Term Notes
SeniorLongTermNotes
130847000
CY2023Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
130594000
CY2023Q4 adma Senior Notes Payable Before Debt Discount
SeniorNotesPayableBeforeDebtDiscount
135000000
CY2024Q1 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2023Q4 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
231769765
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
226063032
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
33596877
CY2024Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
34633358
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
4000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1977514
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
169651
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
85784
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
34800
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2141000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1110000
CY2024Q1 adma Plasma Supply Agreement Term
PlasmaSupplyAgreementTerm
P10Y
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1200000
CY2024Q1 adma Number Of Fda Licensed Plasma Collection Facilities
NumberOfFDALicensedPlasmaCollectionFacilities
10
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
81875000
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
42767000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
21821000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3420000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
18401000
CY2024Q1 us-gaap Segment Expenditure Addition To Long Lived Assets
SegmentExpenditureAdditionToLongLivedAssets
2347000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2114000
CY2024Q1 us-gaap Assets
Assets
350875000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56914000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
40401000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-813000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5976000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6789000
CY2023Q1 us-gaap Segment Expenditure Addition To Long Lived Assets
SegmentExpenditureAdditionToLongLivedAssets
1945000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2033000
CY2023Q1 us-gaap Assets
Assets
340788000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
81875000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56914000
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
600000
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
600000
CY2024Q1 adma Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
10600000
CY2023Q4 adma Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
10800000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y4M24D
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1802000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2421000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2157000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2041000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2088000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2109000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4041000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
16659000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6079000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1093000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9487000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000
CY2024Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.032
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
584000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
4639000
CY2024Q1 adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
1351000
CY2023Q1 adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
530000
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001140361-24-025226-index-headers.html Edgar Link pending
0001140361-24-025226-index.html Edgar Link pending
0001140361-24-025226.txt Edgar Link pending
0001140361-24-025226-xbrl.zip Edgar Link pending
adma-20240331.xsd Edgar Link pending
ef20026261_10q.htm Edgar Link pending
ef20026261_ex31-1.htm Edgar Link pending
ef20026261_ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
adma-20240331_cal.xml Edgar Link unprocessable
adma-20240331_def.xml Edgar Link unprocessable
adma-20240331_lab.xml Edgar Link unprocessable
adma-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ef20026261_10q_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending